Changes in antidepressant metabolism and dosing across pregnancy and early postpartum

Journal of Clinical Psychiatry

Volumn 69, Issue 4, 2008, Pages 652-658

  Sit, Dorothy K ^a   Perel, James M ^a   Helsel, Joseph C ^a   Wisner, Katherine L ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DRUG METABOLITE; ESCITALOPRAM; SERTRALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GESTATION PERIOD; HUMAN; INTERVIEW; MAJOR DEPRESSION; PRIORITY JOURNAL; PUERPERAL DEPRESSION; STEREOISOMERISM;

EID: 44849088194     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0419     Document Type: Article

References (65)

1. Yoon PW, Rasmussen SA, Lynberg MC, et al. The National Birth Defects Prevention Study. Public Health Rep 2001;116(suppl 1):32-40
2. U.S. Food and Drug Administration. Guidance for Industry. Pharmacokinetics in Pregnancy: Study Design, Data Analysis, and Impact on Dosing and Labeling. US Dept Health Human Services 2004; October Issue: 1-14
3. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry 1993;150:1541-1542
4. Wisner KL, Perel JM, Peindl KS, et al. Effects of the postpartum period on nortriptyline pharmacokinetics. Psychopharmacol Bull 1997;33:243-248
5. Hostetter A, Stowe ZN, Strader JR Jr, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000;11:51-57
6. Wadelius M, Darj E, Frenne G, et al. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997;62:400-407
7. Hogstedt S, Lindberg B, Peng DR, et al. Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther 1985;37:688-692
8. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37
9. Prevost RR, Akl SA, Whybrew WD, et al. Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy 1992;12:174-177
10. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005;44:989-1008
11. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006;45:1061-1075
12. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003;61:S35-S42
13. McGready R, Stepniewska K, Seaton E, et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol 2003;59:553-557
14. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 1999;24:339-346
15. Stika C, Frederiksen M. Drug therapy in pregnant and nursing women. In: Atkinson AJ Jr, Daniels CE, Dedrick RL, et al, eds. Principles of Clinical Pharmacology. New York, NY: Academic Press; 2001:277-291
16. Kalra S, Born L, Sarkar M, et al. The safety of antidepressant use in pregnancy. Expert Opin Drug Saf 2005;4:273-284
17. Keller F, Griesshammer M, Haussler U, et al. Pregnancy and renal failure: the case for application of dosage guidelines. Drugs 2001;61:1901-1920
18. Weinstein M. Lithium Treatment of Women During Pregnancy and in the Post-Delivery Period. Lancaster, England: MTP Press; 1980
19. Little B. Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet Gynecol 1999;93:858-868
20. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001;29:1102-1109
21. Hyttel J, Bogeso KP, Perregaard J, et al. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992;88:157-160
22. Sidhu J, Priskorn M, Poulsen M, et al. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 1997;9:686-692
23. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995;6:287-295
24. Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit 2003;25:183-191
25. Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram - a review of pharmacological and clinical effects. J Psychiatry Neurosci 2000;25:241-254
26. Rochat B, Amey M, Gillet M, et al. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997;7:1-10
27. Sanchez C, Bergqvist PB, Brennum LT, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 2003;167:353-362
28. Hyttel J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:277-295
29. Herrlin K, Yasui-Furukori N, Tybring G, et al. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 2003;56:415-421
30. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423
31. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 2005;192:633-639
32. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997;32(suppl 1):22-30
33. Kobayashi K, Ishizuka T, Shimada N, et al. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 1999;27:763-766
34. Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit 2000;22:446-454
35. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition. New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1996
36. Williams JBW, Terman M. Structured Interview Guide for the Hamilton Depression Rating Scale With Atypical Depression Supplement (SIGHADS). New York, NY: New York State Psychiatric Institute; 2003
37. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
38. Williams JBW, Link MJ, Rosenthal NE, et al. Structured Interview Guide for the Hamilton Depression Scale-Seasonal Affective Disorder Version (SIGH-SAD). Revised edition. New York, NY: New York State Psychiatric Institute; 2002
39. Terman M, Terman JS, Williams JBW. Seasonal affective disorder and its treatments. J Pract Psychiatry Behav Health 1998;5:287-303
40. Post RM, Roy-Byrne PP, Uhde TW. Graphic representation of the life course of illness in patients with affective disorder. Am J Psychiatry 1988;145:844-848
41. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991;6(suppl 2):11-21
42. Rochat B, Amey M, Baumann P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit 1995;17:273-279
43. Wisner KL, Hanusa BH, Perel JM, et al. Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol 2006;26:353-360
44. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004;58:119-133
45. Berezhkovskiy LM. Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J Pharm Sci 2004;93:364-374
46. Leinonen E, Lepola U, Koponen H, et al. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 1996;18:111-117
47. Nikisch G, Mathe AA, Czernik A, et al. Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. J Clin Psychopharmacol 2004;24:283-290
48. Bondolfi G, Chautems C, Rochat B, et al. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 1996;128:421-425
49. Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007;164:1206-1213
50. Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002;72:184-191
51. van Heeswijk RP, Khaliq Y, Gallicano KD, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 2004;76:588-597
52. Rudberg I, Hendset M, Uthus LH, et al. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther Drug Monit 2006;28:102-105
53. Yu BN, Chen GL, He N, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 2003;31:1255-1259
54. Sindrup SH, Brosen K, Hansen MG, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15:11-17
55. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-958
56. Sánchez C. R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur J Pharmacol 2003;464:155-158
57. Mørk A, Kreilgaard M, Sánchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003;45:167-173
58. Stórustovu S, Sánchez C, Pörzgen P, et al. R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 2004;142:172-180
59. El Mansari M, Sánchez C, Chouvet G, et al. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005;30:1269-1277
60. Mnie-Filali O, El Mansari M, Espana A, et al. Allosteric modulation of the effects of the 5-HT reuptake inhibitor escitalopram on the rat hippocampal synaptic plasticity. Neurosci Lett 2006;395:23-27
61. El Mansari M, Wiborg O, Mnie-Fifali O, et al. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. Int J Neuropsychopharmacol 2007;10:31-40
62. Beeghly M, Weinberg MK, Olson KL, et al. Stability and change in level of maternal depressive symptomatology during the first postpartum year. J Affect Disord 2002;71:169-180
63. Beeghly M, Olson KL, Weinberg MK, et al. Prevalence, stability, and socio-demographic correlates of depressive symptoms in Black mothers during the first 18 months postpartum. Matern Child Health J 2003;7:157-168
64. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
65. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare Publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health;1976:218-222